Tumors of the Skin

Klein, Edmund; Stoll, Howard L.; Milgrom, Halina; Traenkle, Herbert L.; Case, Robert W.; Laor, Yona; Helm, Frederick; Nadel, Ronald S.

doi:10.1038/jid.1965.163

Cited by 25 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their initial study (8), the effect on nodular basal cell carcinoma was evaluated. The agents, incorporated in ointment or cream, were: .02 percent actinomycin D, 20 percent methotrexate, 20 percent spiramycin, .005 percent nitrogen mus tard, 20 percent 5-mercaptouracil, 10 percent dimethylurethimine, and 20 percent 5-f1uorouracil.…”

mentioning

confidence: 99%

Topical Antimetabolites

Zackheim¹,

Farber²

1970

Annu. Rev. Med.

View full text Add to dashboard Cite

A major advance in dermatologic therapy in the past decade is the suc cessful use of cytotoxic agents by topical application in the treatment of early stages of certain cutaneous malignancies. These include solar keratoses (precursors of squamous cell carcinoma), intraepidermal carcinoma (Bow en's disease), superficial basal cell epithelioma, and early stages of the cu taneous lymphoma, mycosis fungoides. Also responsive to these agents are some virus infections of the skin as herpes simplex, and certain types of warts.5-Fluorouracil (5-FU) is probably the most widely used topical anti metabolite in the treatment of cutaneous precancers. It is a pyrimidine antagonist and alters cell function by inhibiting RNA, and, more important, DNA synthesis. Palliative effects have been produced by 5-FU in a number of human cancers including breast, stomach, large intestine, cervix, and ovary. Falkson & Schultz (1) noted disappearance of solar keratoses in pa tients receiving systemic 5-FU for advanced cancers.The first report of the successful use of topical 5-FU in cutaneous malig nancies was that of Klein et al. (2) who described necrosis of cutaneous me tastases from adenocarcinoma of the colon in two patients following the application of 20 percent 5-FU in a. hydrophilic base. In a subsequent com munication, Klein and co-workers (3) reported the involution of a lesion of keratoacanthoma with a 20 percent 5-FU ointment without damaging the surrounding skin. Injection of a 5 percent solution of 5-FU at the base of other keratoacanthomas also caused destruction of the tumors.In 1963, Dillaha and collaborators (4) reported excellent results in the treatment of extensive actinic keratoses on the face and neck with 20 percent 5-FU in hydrophilic ointment. Eighteen patients were treated with this preparation twice daily. In two to three days an inflammatory reaction was noted at the site of the keratoses without much change in the surrounding skin. The reaction reached its height in about two weeks at which time the medication was stopped. Healing of the lesions occurred in about two more 1 This study on Topical Antimetabolites was supported by a grant from the Hart ford Foundation. 59 Annu. Rev. Med. 1970.21:59-66. Downloaded from www.annualreviews.org Access provided by University of California -San Diego on 02/03/15. For personal use only. Quick links to online content Further ANNUAL REVIEWS

show abstract

mentioning

confidence: 99%

Topical Antimetabolites

Zackheim¹,

Farber²

1970

Annu. Rev. Med.

View full text Add to dashboard Cite

show abstract

Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions

Williams

Klein

1970

Cancer

Self Cite

View full text Add to dashboard Cite

Local chemotherapy with 5‐FU was investigated in premalignant and superficial malignant skin lesions in more than 700 patients. Resolution of neoplasms occurred in more than 95% of patients and lasted for observation periods of up to 6 years. Healing took place without perceptible scarring and with restoration of normal color and texture of the skin. Local side effects were minor. Systemic toxicity did not occur. Several agents, with and without cystostatic activities, produce immune reactions which are more intense at sites of epidermal premalignant and malignant neoplasms than in the normal tissues. More than 50 patients have been studied by this immunotherapeutic approach with results essentially similar to those obtained by topical chemotherapy. Chemotherapy and immunotherapy differ completely in their mechanisms of action. The 2 methods are presented as entirely different modalities, which give essentially similar results. Immunotherapy is still in the investigative stages while local chemotherapy constitutes a modality for the management of extensive skin lesions for which there has been no satisfactory treatment until now.

show abstract

Effect of topical tubercidin on basal cell carcinomas and actinic keratoses

Burgess¹,

Bloch²,

Stoll³

et al. 1974

Cancer

View full text Add to dashboard Cite

The nucleoside Tubercidin was applied topically in a 0.5% concentration to solitary basal cell carcinomas in eight patients and widespread actinic keratoses in five patients for periods of 2–6 weeks. The treatment resulted in complete resolution of all eight basal cell carcinomas. All patients have been followed for 1 1/2 years. No recurrences have been observed. The treatment of the actinic keratoses was unsuccessful in four of five patients treated. These results are in contrast to those produced by topical 5‐fluorouracil, which is less active in basal cell carcinomas and more active against actinic keratoses than Tubercidin.

show abstract

Tumors of the Skin

Cited by 25 publications

References 4 publications

Topical Antimetabolites

Topical Antimetabolites

Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions

Effect of topical tubercidin on basal cell carcinomas and actinic keratoses

Contact Info

Product

Resources

About